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The gastrointestinal tract is inhabited by trillions of individual microbes, representing hundreds to thousands of distinct species. These indigenous organisms are not simply spectators to host activity, but instead actively modulate critical aspects of host physiology. From digestion and the production of small molecules, to the maturation and tuning of immune responses, the gastrointestinal microbiome influences every organ system in the body. Growing experimental evidence demonstrates microbial influence on neurological function in both health and disease. Furthermore, sequencing of the intestinal microbe population reveals altered community structures in various neurological conditions. Here, we provide a perspective on the potential roles for the intestinal microbiome in modulating Parkinson's disease. While Parkinson's disease has been historically studied as a disease of the central nervous system, there is growing appreciation for the roles of both gastrointestinal function and its resident microbes within this disease state. Recent studies focused on the microbiome during Parkinson's disease may advance our understanding of disease etiology and provide perspective for previously unrecognized therapeutic avenues through modulation of intestinal microbes.
Over 200 years ago, James Parkinson reported and described "Shaking Palsy" in several clinical and community observations (Parkinson, 2002) . Parkinson noted the severity and progression of the syndrome, which was characterized by tremors and progressive loss of coordinated motor function. However, the underlying cause of disease was unknown. Based on afflicted individuals' symptoms, as well as a small number of autopsy reports, Parkinson hypothesized that the syndrome was rooted within the central nervous system (CNS) spanning from the medulla spinalis to the medulla oblongata. Additionally, Parkinson suggested that "remote" causes, such as infection or injury in the periphery might be responsible for eliciting damage and dysfunction to these regions of CNS and give rise to the syndrome. Some patients displayed significant gastrointestinal dysfunction (e.g., constipation) and anatomical indicators of bowel inflammation (e.g., darkened color, shortened length). Most enticingly, Parkinson ends his seminal report in 1817 with a description of a man presenting with early stages of the motor disease, in conjunction with severe constipation. Following clearance of the bowel with calomel and Epsom salts for 10 days, the patient no longer displayed the characteristic tremor symptoms of shaking palsy (Parkinson, 2002) .
In present day, the now eponymous Parkinson's disease (PD) is understood to derive from the degeneration of dopaminergic neurons in the substantia nigra pars compacta (SNpc) region of the midbrain (Dijkstra et al., 2014) . These neurons become occluded with aggregations of the amyloid protein, alpha-synuclein (⍺Syn) leading to a variety of cellular and synaptic dysfunctions, which ultimately are thought to lead to an immune-mediated cell death (Brettschneider et al., 2015; Poewe et al., 2017) . Genetic polymorphisms that affect the predisposition of ⍺Syn to aggregate or the ability to maintain cell homeostasis following amyloid insult have been linked to PD (Nalls et al., 2014) . Exposures to environmental toxicants and pesticides that alter ⍺Syn aggregation, protein homeostasis, and/or dopaminergic neuron vulnerability increase PD risk as well (Ritz et al., 2016) . Nonetheless, the majority of PD incidences are idiopathic in the absence of highly penetrant genetic risks and thus likely arise from complex gene-environment interactions (Johnson et al., 2019; Poewe et al., 2017; Ritz et al., 2016) .
Experimental models have demonstrated ⍺Syn propagation in a prion-like fashion through both the CNS and sites in the periphery, including the olfactory bulb, intestine, and muscle to reach the midbrain (Ayers et al., 2017; Breid et al., 2016; Holmqvist et al., 2014; Mason et al., 2016; Rey et al., 2016; Sacino et al., 2014; Uemura et al., 2018) . Based on the progression of both symptoms and pathology from the periphery to the CNS, Braak and colleagues proposed that in some patients Parkinson's disease might initiate at peripheral sites, particularly the nasal cavity and/or intestine (Braak et al., 2003; Del Tredici and Braak, 2008) . Very recent epidemiological evidence suggests that both vagotomy and appendectomy decrease the risk of PD in humans (Killinger et al., 2018; Liu et al., 2017; Svensson et al., 2015) . These exciting observations provide further support that peripheral signals, particularly from the gastrointestinal tract, can contribute to the manifestation of this CNS disease.
The nasal cavity and gastrointestinal tract are not closed systems. These anatomically peripheral sites are exposed to the environment and colonized with a vast consortium of indigenous microbes. It has been estimated that the number of microbial cells in our bodies are equal to, or an order of magnitude greater than our own (Ley et al., 2006) . Additionally, our indigenous microbes may encode up to 100 times more genes than present in the human genome (Qin et al., 2010) . Thus, the native microbial population represents an immense reservoir of unique genetic and chemical outputs that influence numerous aspects of our physiology (Backhed et al., 2005) . The gut microbial population acts as an initial filter for external stimuli (e.g., toxicants, diet), an engine for metabolite production (e.g., digestion of fiber, production of vitamins), and provides signals that influence immune development and responses (Chow et al., 2010) . In light of such broad impacts, the microbiome has drawn increasing attention as a modulator of neurological function (Fung et al., 2017) . With James Parkinson's first report in mind, it is tempting to speculate a role for gut microbes in contributing to the initiation and/or exacerbation of PD, in conjunction with underlying genetic and environmental factors.
In recent years, a large number of studies have been performed to catalog the diversity and abundance of microbial taxa present in the intestinal microbiomes of persons with PD in comparison to healthy individuals (Barichella et al., 2018; Bedarf et al., 2017; Hasegawa et al., 2015; Hill-Burns et al., 2017; Hopfner et al., 2017; Keshavarzian et al., 2015; Li et al., 2017; Lin et al., 2018; Mertsalmi et al., 2017; Minato et al., 2017; Petrov et al., 2017; Scheperjans et al., 2015; Unger et al., 2016) . Among these studies, the majority utilized fecal sampling and 16S rRNA sequencing to assess the gastrointestinal microbiome archetecture. One study to date has performed metagenomic sequencing to resolve the microbial community structure on the level of single genes that are differentially abundant between persons with PD and neurologically healthy individuals (Bedarf et al., 2017) . Across studies there exist some discrepancies in the specific findings, likely due to sample size and technical variations, however the consensus appears that persons with PD have an altered microbial community, or dysbiosis, compared to unafflicted individuals. Utilizing larger study sets (ie. >100 individuals per group), allows for some agreement to appear (Barichella et al., 2018; Hill-Burns et al., 2017) . Most consistently, decreases in the Lachnospiraceae family, including Blautia sp. and Roseburia sp., as well as decreases to Faecalibacterium, have been reported. Taxa enriched in PD include the Lactobacillaceae family, Akkermansia sp. and Bifidiobacterium sp. Further taxonomic differences between studies are detailed in Table 1 . Stratification of PD patients into tremordominant or postural instability and gait-dominant forms revealed that persons with the more severe postural instability form displayed increased abundance of the family Enterobacteraceae in fecal-derived samples (Li et al., 2017; Scheperjans et al., 2015) . Lactobacillaceae also appear positively correlated with disease severity (Barichella et al., 2018; Hasegawa et al., 2015; Lin et al., 2018) . Such associations provide support that dysbiosis appears in PD, although the directionality and cause-effect relationships between microbes and disease in humans are not known.
Fecal-derived microbial communities are easily observed. Unlike tissue or small intestinal contents, they do not require invasive procedures to acquire. However, the microbiome present in the feces is not identical to that within other regions of the gastrointestinal tract. The small intestine harbors a distinct microbial community compared to what is observed in feces (Donaldson et al., 2016) , and this specific microbial population has not yet been assessed in the context of PD. Even within the colon, fecal/ luminal microbial communities are not identical to those microbes that thrive within the colonic mucosa (Donaldson et al., 2016) . Microbes more closely associated with tissue may be candidates for direct actors on host functions. Currently, one study has specifically compared mucosa-associated microbes in PD, identifying increased members of the Oxalobacteraceae family and decreased Faecalibacterium sp. in sigmoid mucosal biopsies derived from persons with PD and matched controls. (Keshavarzian et al., 2015) . Direct observation of bacteria within the mucosa and associated with the colonic epithelia through immunohistology has revealed increased Enterobacteraceae abundance, specifically Escherichia coli, within the intestinal mucosa of persons with PD (Forsyth et al., 2011) . Further, while focus has been directed on the GI tract, altered oral (but not nasal) microbiomes have been observed in persons with PD as well , providing another host-microbe interface to be explored that correlates with olfactory deficits that precede PD diagnosis (Braak et al., 2003; Tarakad and Jankovic, 2017) .
Although these studies provide a cataloging of bacterial taxa, other microorganisms-archaea, viruses/bacteriophage, and fungi are also present within the GI tract (Lozupone et al., 2012) . Sequencing of GI tract-resident viruses has revealed alterations to the bacteriophage community (Bedarf et al., 2017; Tetz et al., 2018) . These studies indicate a lower total abundance of bacteriophage and viruses in persons with PD (Bedarf et al., 2017) . Further analyses of this dataset revealed decreases in overall bacteriophage diversity in persons with PD, and an increase in lytic bacteriophage associated with Lactococcus sp. (Tetz et al., 2018) . Bacteriophage undoubtedly play a pivotal role in the homeostasis of the GI microbiome, but precisely how their abundance and diversity may alter microbiome architecture is largely unknown. Further, these studies are restricted by the relatively limited number of sequenced bacteriophage genomes present within databases used to assess microbial communities, as well as a distinct bias of sequencing bacteriophages with host organisms that are easily culturable.
While important, descriptive studies of microbiome architecture between persons with PD and controls are unable to indicate whether dysbiosis influences disease, in a cause-effect manner. It is critical to determine whether the dysbiosis present during PD has functional contributions, with microbes as active instigators or modulators of disease state. Alternatively, dysbiosis may arise due to the inherent changes in the hosts' physiology (e.g. functional constipation) and the microbial population is affected as a bystander. In the latter case, dysbiosis would not be causative or influential on PD, but instead be an epiphenomenon. With strong correlations between disease and specific microbial taxa, even as an epiphenomenon the microbiome may ultimately be a useful tool as an accessible biomarker for the diagnosis and progression of PD. Correlating patient disease severity and progression kinetics, or identifying microbial shifts that occur early in disease, may allow for earlier or more targeted application of treatment options. Current and ongoing metagenomic studies cataloging the entirety of encoded microbial genes (Bedarf et al., 2017) , in conjunction with metabolomic analysis, will provide further insight into the potential functional changes within the microbiome that may modify PD-relevant host physiologies.
Experimental evidence supporting a functional role for gut microbes in impacting disease outcomes in PD is beginning to surface. In one study, eliminating microbial signals in ⍺Syn-overexpressing mice through either germ-free rederivation or microbial depletion with antibiotics decreased ⍺Syn amyloid deposition in the brain, neuroinflammation, and motor deficits (Sampson et al., 2016) . Antibiotic treatment has been shown to also dampen MPTP toxin-induced models of PD by preventing ⍺Syn aggregation and dopaminergic cell death (Bisht et al., 2014; Du et al., 2001; Jing et al., 2017; Kaur and Prakash, 2017) . Conversely, norovirus infection correlates with increased synuclein production within the GI tract, suggesting that microbial signals can elicit ⍺Syn pathology (Stolzenberg et al., 2017) . Similar microbial modulation of pathology has been observed in other models of amyloid disease. In two different mouse models of amyloid-β deposition, representing Alzheimer's disease, germ-free status or antibiotic treatment decreased amyloid-β pathology in relevant brain regions (Harach et al., 2017; Minter et al., 2017; Minter et al., 2016) . It is exciting to consider the possibility of shared mechanisms of microbial influence within the gastrointestinal tract on the deposition of amyloid proteins in the brain that are central to neurodegenerative disease.
These studies have focused on the depletion of microbes on PD models, providing some early evidence for functional contributions to disease. It is therefore necessary to begin addressing whether specific bacterial taxa or microbial products play a role in these experimental
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Neurobiology of Disease xxx (xxxx) xxxx observations. Colonization of germ-free animal models with defined microbial communities or individual microbes will enable microbial contributions to disease characteristics to be experimentally dissected. For instance, germ-free ⍺Syn-overexpressing mice were colonized with complex communities of human-derived fecal microbes, originating from healthy individuals or persons with PD. It was observed that those ⍺Syn-overexpressing mice colonized with PD-derived microbes performed worse in motor performance tests than those colonized with microbes derived from the healthy individuals (Sampson et al., 2016) . Analysis of the microbial community composition revealed that those animals displaying the most motor dysfunction (i.e., those with ⍺Synoverexpression and receiving PD-derived microbes) harbored a number of changes to microbial taxa. These alterations may suggest the presence of microbes that exacerbate disease in the model, or instead, the absence of microbes that may dampen a disease state. One of the indicated community differences in the above experiment is the increased abundance of the family Enterobacteraceae, specifically Proteus sp. in the ⍺Syn-overexpressing mice humanized with PD-derived microbes (Sampson et al., 2016) . This finding recapitulates data from human communities, demonstrating increased Proteus sp. enrichment, greater Enterobacteraceae abundance and mucosal localization in persons with PD (Forsyth et al., 2011; Li et al., 2017; Lin et al., 2018; Scheperjans et al., 2015; Unger et al., 2016) . Interestingly, Proteus sp. are one of the primary microbes involved in small intestinal bowel overgrowth (SIBO), a pathology due to increased bacterial load within the small intestine (Pyleris et al., 2012) . Persons with PD often exhibit SIBO, and this comorbidity is correlated with worsened motor symptoms (Tan et al., 2014) . While intriguing, to our knowledge, specifically inducing SIBO in experimental models of PD has not yet been performed. There is, instead, experimental evidence demonstrating that enrichment of Proteus mirabilis into mice (not necessarily inducing SIBO), increases their susceptibility to MPTP (Choi et al., 2018) . Oral exposure to P. mirabilis in conjunction with MPTP resulted in increased loss of dopaminergic neurons in the SNpc and worsened motor impairment compared to MPTP treatment alone in a mouse model (Choi et al., 2018) . In fact, oral treatment with P. mirabilis alone, even in the absence of MPTP exposure, damaged nigral dopaminergic neurons (Choi et al., 2018) . This suggests that microbial signals originating in the GI tract, and from Proteus sp. specifically, may act to predispose the host to PD-relevant neuronal damage. It is hypothesized that P. mirabilis lipopolysaccharide (LPS), an inflammatory component of the Gramnegative cell envelope, may act to instigate inflammation leading to ⍺Syn accumulation and dopaminergic neuron vulnerability (Choi et al., 2018) . However, numerous gut microbes produce a similarly structured LPS capable of stimulating inflammatory responses (Raetz and Whitfield, 2002) , and this alone cannot account for the predicted specificity of this interaction. The identification of signals specific to P. mirabilis, how they are transduced from the GI tract to the CNS, and how they act to elicit dopaminergic neuron vulnerability is currently unknown. Yet, these data provide the foundation for host-pathogen experimental models to understand the contribution of a specific gut microbe to PD pathophysiology.
In a similar fashion, another member of the Enterobacteraceae family, E. coli, has been experimentally demonstrated to increase inflammatory markers and ⍺Syn aggregation in the brains of rats following oral exposure (Chen et al., 2016) . Corresponding to the observation of increased Enterobacteraceae in more severe PD incidences (Li et al., 2017; Scheperjans et al., 2015) , as well as increased E. coli presence in the intestinal mucosa of persons with PD (Forsyth et al., 2011) , these experimental data suggest that there may be diseaserelevant affects directly due to the increases of E. coli in the GI tract. As with the observations with P. mirabilis, the precise signaling contributions of E. coli leading to PD-relevant changes in physiology are not completely elucidated. Similar to P. mirabilis, E. coli generates a proinflammatory LPS molecule that may act to maintain a chronic, systemic inflammatory response with effects on CNS function (Forsyth et al., 2011) .
More intriguing is the observation that E. coli produces an extracellular structure, termed curli, which takes on an amyloid form similar to pathogenic ⍺Syn (Tursi and Tukel, 2018) . Production of curli, encoded by the gene csgA, is an important factor to E. coli lifestyle. Curli amyloids are not "misfolded" as canonically thought of during eukaryotic amyloid diseases, such as PD. Instead, curli amyloids provide a mechanism of surface attachment, immune evasion, and defense against bacteriophages (Ellermann and Sartor, 2018; Hufnagel et al., 2013; Vidakovic et al., 2018) . When rats were exposed to E. coli that could not produce curli amyloids, neuroinflammation and ⍺Syn aggregation that occurred upon exposure to wild-type E. coli, did not occur as robustly (Chen et al., 2016) . This suggests that rather than LPS signaling alone, the production of this bacterial amyloid could provide a specific signal from the GI tract that can impact PD-relevant physiologies in the brain. How curli may act to elicit these changes is largely unknown. Curli may act to stimulate inflammatory responses, or based on its structure, may have the potential to template the generation of ⍺Syn amyloids and directly drive PD pathology (Friedland and Chapman, 2017) . It is also unknown whether curli abundance specifically (rather than Enterobacteraceae abundance, generally) within the GI tract correlates with disease status or alters the progressive motor dysfunction observed in PD or PD-relevant animal models. Nonetheless, these data provide support for continued exploration of specific microbial factors with the ability to modulate outcomes in PD models. Interestingly, Enterobacteraceae (including Proteus sp. and Escherichia sp.) are also enriched within the vermiform appendix (Guinane et al., 2013; Schulin et al., 2017) . Although interpretation of this finding is difficult, as these sites are sampled during acute appendicitis and may not represent a healthy microbiome. However, with recent data indicating a decreased risk and later onset of PD diagnosis following appendectomy (Killinger et al., 2018) , it is interesting to consider the impact of Enterobacteraceae within this tissue on disease. Further application of microbial genetics and host-microbe biology towards the study of PD has potential to identify myriad mechanisms of microbial influence.
While the previous examples have focused on pathogenic aspects of the microbiome on PD, there also exists the possibility of beneficial interactions that are missing or decreased due to PD dysbiosis. For example, there may be microbes that produce molecules that dampen inflammation or inhibit the aggregation of ⍺Syn, ultimately preventing disease initiation or slowing its progression. There are many examples of beneficial microbes that are capable of specifically dampening inflammatory responses within the GI tract (Chung and Kasper, 2010) . In line with this, one experimental study of fecal microbial transplant (FMT) demonstrated that mice receiving a healthy microbial population were protected from dopaminergic neuron death following MPTP treatment (Sun et al., 2018) . It is unknown which bacterial taxa or metabolites may be mediating these effects. Future efforts to explore beneficial microbes in other models of PD will be critical to identify potential probiotic type treatments that may be useful in clinical applications. Recently, an epidemiological association between inflammatory bowel disease (IBD) and subsequent diagnosis of PD has been identified (Hui et al., 2018; Peter et al., 2018) . IBD has a strong microbial component and FMT has promise in rescue of symptoms (Moayyedi, 2018) . Rigorous comparison of IBD and PD microbiomes has yet to be performed, but cursory examination of altered taxa reveals some similar changes within each disease-associated microbiome. Decreases in Lachnospiraceae, Prevotella sp., and Faecalibacterium sp. appear consistently in both IBD and PD (Halfvarson et al., 2017; Hill-Burns et al., 2017; Scheperjans et al., 2015) . It is therefore exciting to consider FMT in an effort to restore the microbiome, limit GI inflammation, and perhaps reduce future risk of PD. Or, more coercively, even limit the existing progression of disease, as Parkinson observed in his case study 200 years ago (Parkinson, 2002) . In fact, a well-designed study has recently commenced (January 2019) to examine the effect of FMT intervention on the progression of motor and non-motor dysfunctions in PD (Clinicaltrials.gov ID: NCT03808389).
While data demonstrating that persons with PD harbor a dysbiotic intestinal microbiome continue to accumulate, one pressing question is how the dysbiosis initially arises. Certainly, physiological changes, such as constipation, which occurs early in PD can shift the population of the gut microbiome (Zhao and Yu, 2016) . Diet is also well established to shape the intestinal microbiome (Singh et al., 2017) , however links between diet and PD are tenuous (Erro et al., 2018) . Pharmaceutical interventions also have an effect on the microbiome structure, but even with this confounding variable taken into account, dysbiosis during PD is still apparent (Bedarf et al., 2017; Hill-Burns et al., 2017; Scheperjans et al., 2015) . Helicobacter pylori infection, the causative agent of peptic ulcer, is associated with PD . During H. pylori infection, acidification of the upper GI tract decreases and may alter the distal microbial population. Environmental exposures to pollutants, particularly to pesticides, are strongly linked to increased PD risk (Ritz et al., 2016) . Some experimental evidence exists for pesticide exposure to alter the intestinal microbiome (Gao et al., 2018; Lai et al., 2018) . To our knowledge, no study to date has explored changes to the mammalian gut microbiome following PD-relevant pesticide exposures. The microbiome of persons with PD are indeed enriched for microbial genes that are involved in the metabolism of xenobiotics (Barichella et al., 2018; Hill-Burns et al., 2017) , suggesting that environmental exposures impact microbiome structure. While pesticides can act directly on neurons and affect their physiology, pesticide-induced shifts in the intestinal microbiome may exacerbate long-lasting effects of exposure. Analysis of exposed microbiomes in an experimental setting, in comparison to that found in persons with PD, will reveal whether pesticide exposure can shift the microbiome towards the structure associated with PD. Further functional studies through colonization of germ-free animals with these shifted populations may reveal chemical-independent, microbiomedependent effects on PD-relevant pathophysiologies.
The recent observations described herein represent some of the first experimental examples of microbiome effects on PD-relevant animal models. Even with these initial identifications of specific influential microbes, it is largely unknown how these microbes impact critical physiology that relates to PD. It will be essential to identify the microbial factors, and subsequently the host pathways that are being modulated. For instance, intestinal microbes can drive inflammatory responses in both the periphery and the CNS. Can such intestinallyderived inflammation alter the vulnerability of the nigral system? There is evidence for increased intestinal permeability in persons with PD (Forsyth et al., 2011) . Does this result in increased translocation of specific bacterial metabolites that can enter circulation, cross the bloodbrain-barrier and directly influence dopaminergic neuron physiology? Or, instead, are specific molecules produced in the intestinal lumen that instigate ⍺Syn propagation via vagus nerve, and/or effect ENS and vagal signaling leading to disruption of CNS function? Likely myriad mechanisms of microbial modulation exist. By utilizing the large-scale population sequencing and metabolomics data derived in the human condition to generate testable hypotheses, gnotobiotic models will be able to experimentally address these new questions. The intersection of host-microbe interactions and PD may subsequently offer new insights into the etiology of this disease. Two hundred years ago, James Parkinson recognized a potential for gastrointestinal intervention in the treatment of this CNS disease. With a renewed interested today, ongoing work in this field will identify new avenues for therapeutic discovery focused on the gastrointestinal tract and its resident microbes.
